An evidence-based systematic review of green-lipped mussel (Perna canaliculus) by the natural standard research collaboration

Journal of Dietary Supplements

Volumn 6, Issue 1, 2009, Pages 54-90

  Ulbricht, Catherine ^a   Chao, Wendy ^b   Costa, Dawn ^b   Nguyen, Yen ^b   Seamon, Erica ^c   Weissner, Wendy ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Natural Standard   (United States)

^c NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Adverse effects; Dosing; Evidence based; Green lipped mussel (perna canaliculus); Interactions; Pharmacodynamics; Pharmacokinetics; Pharmacology; Systematic review

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; LIPID;

ANIMAL; ARTICLE; CHEMISTRY; COOPERATION; DIET SUPPLEMENTATION; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; PERNA; PREGNANCY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AGENTS; COOPERATIVE BEHAVIOR; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LIPIDS; PERNA; PREGNANCY;

ANIMALIA; PERNA; PERNA CANALICULUS;

EID: 61849164030     PISSN: 19390211     EISSN: None     Source Type: Journal    
DOI: 10.1080/19390210802690191     Document Type: Article

References (68)

1. Ahern MJ, Milazzo SC, Dy mock R. Granulomatous hepatitis and Seatone. Med J Aust. 1980;2(3): 151-152.
2. Audeval B, Bouchacourt P. Etude contrôlée, en double aveugle contre placebo, de l'extrait de moule Perna canaliculus (moule aux orles verts) dans la gonarthose (Double blind, placebo-controlled study of the mussel Perna canaliculus (New Zealand green-lipped mussel) in arthritis of the knee). La Gazette. 1986;93:111-116.
3. Bierer TL, Bui LM. Improvement of arthritic signs in dogs fed green-lipped mussel (Perna canaliculus). J Nutr. 2002; 132(6 Suppl 2): 1634S-1636S.
4. Brien S, Prescott P, Coghlan B, Bashir N, Lewith G. Systematic review of the nutritional supplement Perna Canaliculus (green-lipped mussel) in the treatment of osteoarthritis. QJM. 2008; 101 (3): 167-179.
5. Brooks PM. Side effects from Seatone. Med J Aust. 1980;2(3): 158.
6. Bui LM, Bierer TL. Influence of green lipped mussels (Perna canaliculus) in alleviating signs of arthritis in dogs. Vet Ther. 2003;4(4):397-407.
7. Butters DE, Whitehouse MW. Treating inflammation: some (needless) difficulties for gaining acceptance of effective natural products and traditional medicines. Inflammopharmacology. 2003; 11(1 ):97-l10.
8. Caughey DE, Grigor RR, Caughey EB, Young P, Gow PJ, Stewart AW. Perna canaliculus in the treatment of rheumatoid arthritis. Eur J Rheumatol Inflamm. 1983;6(2): 197-200.
9. Cho SH, Jung YB, Seong SC, Park HB, Byun KY, Lee DC, Song, E. K., Son, J. H. Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial. Eur Ann Allergy Clin Immunol. 2003;35(6):212-216.
10. Cobb CS, Ernst E. Systematic review of a marine nutriceutica) supplement in clinical trials for arthritis: the effectiveness of the New Zealand green-lipped mussel Perna canaliculus. Clin Rheumatol. 2006;25(3):275-284.
11. Couch RA, Ormrod DJ, Miller TE, Watkins WB. Anti-inflammatory activity in fractionated extracts of the green-lipped mussel. N Z Med J. 1982;95(720):803-806.
12. Croft JE. Granulomatous hepatitis and Seatone. Med J Aust. 1980;2(7):401-402.
13. Darlington LG, Ramsey NW. Review of dietary therapy forrheumatoid arthritis. Compr Ther. 1994;20(9):490-494.
14. Dugas B. Lyprinol inhibits LTB4 production by human monocytes. Allerg Immunol (Paris). 2000;32(7):284-289.
15. Emelyanov A, Fedoseev G, Krasnoschekova O, Abulimity A, Trendeleva T, Barnes PJ. Treatment of asthma with lipid extract of New Zealand green-lipped mussel: a randomised clinical trial. Eur Respir J. 2002;20(3):596-600.
16. Fabrin B. Possible toxic hepatitis after intake of an alternative preparation. Ugeskr Laeger. 1988; 150(24): 1474-1475.
17. Ferreira SH. Proposal to use pentoxifylline and Lyprinol therapy for chronic inflammatory diseases. Inflammopharmacology. 2005;13(5-6):429-430.
18. Gibson SL. The effect of a lipid extract of the New Zealand green-lipped mussel in three cases of arthritis. J Altern Complement Med. 2000;6(4):351-354.
19. Gibson RG, Gibson SL. Green-lipped mussel extract in arthritis. Lancet. 1981a;l(8217):439.
20. Gibson RG, Gibson SL. Seatone in arthritis. Br Med J (Clin Res Ed). 1981b; 282(6278): 1795.
21. Gibson RG, Gibson SL. New Zealand green-lipped mussel extract (Seatone) in rheumatoid arthritis. N Z Med J. 1981c;94(688):67-68.
22. Gibson RG, Gibson SL. Seatone in rheumatoid arthritis. Ann Rheum Dis. 1985;44(9):645-646.
23. Gibson SL, Gibson RG. The treatment of arthritis with a lipid extract of Perna canaliculus: a randomised trial. Comp Ther Med. 1998;6:122-126.
24. Gibson RG, Gibson SL, Conway V, Chappell D. Perna canaliculus in the treatment of arthritis. Practitioner. 1980;224(1347):955-960.
25. Glass WI, Power P, Burt R, Fishwick D, Bradshaw LM, Pearce NE. Work-related respiratory symptoms and lung function in New Zealand mussel openers. Am J Ind Med. 1998;34(2): 163-168.
26. Green-lipped mussel extract in arthritis. Lancet. 1981; 1 (8211):85.
27. Greening GE, Dawson J, Lewis G. Survival of poliovirus in New Zealand green-lipped mussels, Perna canaliculus, on refrigerated and frozen storage. J Food Prot. 2001 ;64(6): 881-884.
28. Gruenwald J, Graubaum H, Hansen K, Grube B. Efficacy and tolerability of a combination of LYPRINOL and high concentrations of EPA and DHA in inflammatory rheumatoid disorders. Adv Ther. 2004;21(3): 197-201.
29. Halliday J. Not all green lipped mussel extracts are created equal. Nutralngredients.com Europe. Nutra Ingredients - Europe 2008.
30. Halpern GM. An anti-inflammatory from the South Seas: Lyprinol. Allerg Immunol (Paris). 2000a;32(7):259-260.
31. Halpern GM. Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol). Allerg.Immunol (Paris). 2000b;32(7):272-278.
32. Halpern C, Georges M. Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol). Townsend Lett Dr Patients. 2000;(202): 109-113.
33. Highton TC, McArthur AW. Pilot study on the effect of New Zealand green mussel on rheumatoid arthritis. N Z Med J. 1975;81(535):261-262.
34. Huskisson EC, Scott J, Bryans R. Seatone is ineffective in rheumatoid arthritis. Br Med j (Clin Res Ed). 1981;282(6273): 1358-1359.
35. Ishida H, Nozawa A, Nukaya H, Rhodes L, McNabb P, Holland PT, Tsuji, K. Confirmation of brevetoxin metabolism in cockle, Austrovenus stutchburyi, and greenshell mussel, Perna canaliculus, associated with New Zealand neurotoxic shellfish poisoning, by controlled exposure to Karenia brevis culture. Toxicon. 2004;43(6):701-712.
36. Jacobs JW, Rasker JJ, Van Riel PL, Gribnau FW, van de Putte LB. Alternative treatment methods in rheumatic diseases; a literature review. Ned Tijdschr Geneeskd. 1991; 135(8):317-322.
37. Kendall RV, Lawson JW, Hurley LA. New research and a clinical report on the use of Perna canaliculus in the management of arthritis. Townsend Lett Dr Patients. 2000;204(98):111.
38. Kosuge T, Tsuji K, Ishida H, Yamaguchi T. Isolation of an anti-histaminic substance from green-lipped mussel (Perna canaliculus). Chem Pharm Bull (Tokyo). 1986;34(11):4825-4828.
39. Larkin JG, Capell HA, Sturrock RD. Seatone in rheumatoid arthritis: a six-month placebo-controlled study. Ann Rheum Dis. 1985;44(3): 199-201.
40. Lau S, Chiu PK, Chu EMY, Cheng IYW, Tang WM, Man RYK, Halpern, G. M. Treatment of knee osteoarthritis with Lyprinol, lipid extract of the green-lipped mussel - a double-blind placebo-controlled study. Prog Nutr. 2004;61(17): 17-31.
41. Lawson BR, Belkowski SM, Whitesides JF, Davis P, Lawson JW. Immunomodulation of murine collagen-induced arthritis by N, N-dimethylglycine and a preparation of Perna canaliculus. BMC Complement Altern Med. 2007,7:20.
42. MacKenzie L, Holland P, McNabb P, Beuzenberg V, Selwood A, Suzuki T. Complex toxin profiles in phytoplankton and Greenshell mussels (Perna canaliculus), revealed by LC-MS/MS analysis. Toxicon. 2002;40(9):1321-1330.
43. Mani S, Lawson JW. In vitro modulation of inflammatory cytokine and lgG levels by extracts of Perna canaliculus. BMC Complement Altern Med. 2006;6:1.
44. McPhee S, Hodges LD, Wright PF, Wynne PM, Kalafatis N, Harney DW, Macrides, T. A. Anti-cyclooxygenase effects of lipid extracts from the New Zealand green-lipped mussel, Perna canaliculus. Comp Biochem Physiol B Biochem Mol Biol. 2007;146(3):346-356.
45. Meletis CD. Natural relief for inflammation of sprains, strains, and arthritis. Alt Comp Ther. (England) 2000;6:141-144.
46. Miles CO, Wilkins AL, Munday R, Dines MH, Hawkes AD, Briggs LR, Sandvik, M., Jensen, D. J., Cooney, J. M., Holland, P. T., Quilliam, M. A., MacKenzie, A. L., Beuzenberg, V., Towers, N. R. Isolation of pectenotoxin-2 from Dinophysis acuta and its conversion to pectenotoxin-2 seco acid, and preliminary assessment of their acute toxicities. Toxicon. 2004;43(l):l-9.
47. Miller TE, Ormrod D. The anti-inflammatory activity of Perna canaliculus (NZ green lipped mussel). N Z Med J. 1980,92(667): 187-193.
48. Miller TE, Dodd J, Ormrod DJ, Geddes R. Anti-inflammatory activity of glycogen extracted from Perna canaliculus (NZ green-lipped mussel). Agents Actions. 1993;38 Spec No:C139-C142.
49. Miller T, Wu H. In vivo evidence for prostaglandin inhibitory activity in New Zealand green-lipped mussel extract. N Z Med J. 1984;97(757):355-357.
50. Morohashi A, Satake M, Naoki H, Kaspar HF, Oshima Y, Yasumoto T. Brevetoxin B4 isolated from greenshell mussels Perna canaliculus, the major toxin involved in neurotoxic shellfish poisoning in New Zealand. Nat Toxins. 1999;7(2):45-48.
51. Murphy KJ, Mann NJ, Sinclair AJ. Fatty acid and sterol composition of frozen and freeze-dried New Zealand Green Lipped Mussel (Perna canaliculus) from three sites in New Zealand. Asia Pac J Clin Nutr. 2003;12(1):50-60.
52. New Zealand green-lipped mussel extract (Seatone) and rheumatoid arthritis. N Z Med J. 1981;93(684):343.
53. Anon. Aussies to test Lyprinol. International Council for Health Freedom Newsletter 1999;3(3/4):45.
54. Pollard B, Guilford WG, Ankenbauer-Perkins KL, Hedderley D. Clinical efficacy and tolerance of an extract of green-lipped mussel (Perna canaliculus) in dogs presumptively diagnosed with degenerative joint disease. N Z Vet J. 2006;54(3): 114-118.
55. Scotti PD, Dearing SC, Greenwood DR, Newcomb RD. Pernin: a novel, self-aggregating haemolymph protein from the New Zealand green-lipped mussel, Perna canaliculus (Bivalvia: Mytilidae). Comp Biochem Physiol B Biochem Mol Biol. 2001;128(4):767-779.
56. Shiels I A, Whitehouse MW. Lyprinol: anti-inflammatory and uterine-relaxant activities in rats, with special reference to a model for dysmenorrhoea. Allerg Immunol (Paris). 2000;32(7):279-283.
57. Sinclair AJ, Murphy KJ, Li D. Marine lipids: overview "news insights and lipid composition of Lyprinol". Allerg Immunol (Paris). 2000;32(7):261-271.
58. Singh M, Hodges LD, Wright PF, Cheah DM, Wynne PM, Kalafatis N, Macrides, T. A. The C02-SFE crude lipid extract and the free fatty acid extract from Perna canaliculus have anti-inflammatory effects on adjuvant-induced arthritis in rats. Comp Biochem Physiol B Biochem Mol Biol. 2008; 149(2):251-258.
59. Suzuki T, MacKenzie L, Stirling D, Adamson J. Pectenotoxin-2 seco acid: a toxin converted from pectenotoxin-2 by the New Zealand Greenshell mussel, Perna canaliculus. Toxicon. 2001;39(4):507-514.
60. Tenikoff D, Murphy KJ, Le M, Howe PR, Howarth GS. Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease. J Gastroenterol. 2005;40(4):361-365.
61. Torres DM, Tooley KL, Butler RN, Smith CL, Geier MS, Howarth GS. Lyprinol only partially improves indicators of small intestinal integrity in a rat model of 5-fluorouracil-induced mucositis. Cancer Biol Ther. 2008;7(2):295-302.
62. Treschow AP, Hodges LD, Wright PF, Wynne PM, Kalafatis N, Macrides TA. Novel anti-inflammatory omega-3 PUFAs from the New Zealand green-lipped mussel, Perna canaliculus. Comp Biochem Physiol B Biochem Mol Biol. 2007; 147(4):645-656.
63. Whitehouse MW. Call for a trial of Lyprinol, an over-the-counter 5-lipoxygenase inhibitor: comment on the article by Kowal-Bielecka et al. Arthritis Rheum. 2002;46(7): 1977-1978.
64. Whitehouse MW. Anti-TNF-alpha therapy for chronic inflammation: reconsidering pentoxifylline as an alternative to therapeutic protein drugs. Inflammopharmacol-ogy. 2004;12(3):223-227.
65. Whitehouse MW. Prostanoids as friends, not foes: further evidence from the interference by cycloxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats. Inflammopharmacology. 2005; 12(5-6):481-492.
66. Whitehouse MW, Macrides TA, Kalafatis N, Betts WH, Haynes DR, Broadbent J. Anti-inflammatory activity of a lipid fraction (lyprinol) from the NZ green-lipped mussel. Inflammopharmacology. 1997;5(3):237-246.
67. Wolyniak CJ, Brenna T, Murphy KJ, Sinclair AJ. Gas chromatography- chemical ionization-mass spectrometric fatty acid analysis of a commercial supercritical carbon dioxide lipid extract from New Zealand green-lipped mussel (Perna canaliculus). Lipids. 2005;40(4):355-360.
68. Yuan G, Wahlqvist ML, He G, Yang M, Li D. Natural products and anti-inflammatory activity. Asia Pac J Clin Nutr. 2006; 15(2): 143-152.